Per Odin, MD, PhD, Lund University, Lund, Sweden, outlines the advanced treatment options available for the management of Parkinson’s disease, including intraventricular levodopa (L-dopa), subcutaneous apomorphine, and deep brain stimulation. Further alternatives for continuous dopaminergic delivery, such as subcutaneous infusion of L-dopa, are currently under development. The continuous stimulation of the dopamine receptors improves levodopa-related motor complications and ultimately improves the quality of life of patients with Parkinson’s disease. This interview took place at the 2022 International Congress of Parkinson’s disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.